A common drug slashes your risk of hospitalisation after Covid by as much as a third.
An antidepressant costing just 29p was given to half in a new study, with the other participants getting a placebo.
The study took place in Brazil, in South America, and its research has now been published in the Lancet.
…Fluvoxamine is branded as Faverin in the UK, and was found to reduce the hospital risk by 32 per cent in Covid sufferers.
Edward Mills, a researcher at McMaster University, Canada, which co-led the study, said: “Fluvoxamine is, so far, the only treatment that if administered early, can prevent Covid-19 from becoming a life-threatening illness.
So, it seems that Long Covid is not as widespread as we were told it was. More importantly – and, yes, this is the more difficult thing to discuss – maybe Long Covid is not as real as we were told it was, either. Maybe the fairly typical problems that a minority of people experience after a virus were, in this case, unjustifiably blown up into a whole new sickness. Alongside examining the measurable, physical prevalence of long-lasting symptoms in people who have been infected with Covid – something it is very important for society to do – we must also analyse the cultural components to Long Covid. How much did the culture of fear around Long Covid help to convince people that they had it? And did a broader culture of victimhood likewise help to coax people to self-identify as suffering from this new, seemingly fascinating ailment, and even to embrace Long Covid as a kind of identity?